Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia

Stephen S. Chung, Eunhee Kim, Jae H. Park, Young Rock Chung, Piro Lito, Julie Teruya-Feldstein, Wenhuo Hu, Wendy Beguelin, Sebastien Monette, Cihangir Duy, Raajit Rampal, Leon Telis, Minal Patel, Min Kyung Kim, Kety Huberman, Nancy Bouvier, Michael F. Berger, Ari M. Melnick, Neal Rosen, Martin S. TallmanChristopher Y. Park, Omar Abdel-Wahab

Research output: Contribution to journalArticlepeer-review

106 Scopus citations


Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder characterized by somatic BRAFV600E mutations. The malignant cell in HCL has immunophenotypic features of a mature B cell, but no normal counterpart along the continuum of developing B lymphocytes has been delineated as the cell of origin. We find that the BRAFV600E mutation is present in hematopoietic stem cells (HSCs) in HCL patients, and that these patients exhibit marked alterations in hematopoietic stem/progenitor cell (HSPC) frequencies. Quantitative sequencing analysis revealed a mean BRAFV600E-mutant allele frequency of 4.97% in HSCs from HCL patients. Moreover, transplantation of BRAFV600E-mutant HSCs from an HCL patient into immunodeficient mice resulted in stable engraftment of BRAFV600E-mutant human hematopoietic cells, revealing the functional self-renewal capacity of HCL HSCs. Consistent with the human genetic data, expression of BRaf V600E in murine HSPCs resulted in a lethal hematopoietic disorder characterized by splenomegaly, anemia, thrombocytopenia, increased circulating soluble CD25, and increased clonogenic capacity of B lineage cells - all classic features of human HCL. In contrast, restricting expression of BRafV600E to the mature B cell compartment did not result in disease. Treatment of HCL patients with vemurafenib, an inhibitor of mutated BRAF, resulted in normalization of HSPC frequencies and increased myeloid and erythroid output from HSPCs. These findings link the pathogenesis of HCL to somatic mutations that arise in HSPCs and further suggest that chronic lymphoid malignancies may be initiated by aberrant HSCs.

Original languageEnglish
Article number238ra71
JournalScience Translational Medicine
Issue number238
StatePublished - 28 May 2014
Externally publishedYes


Dive into the research topics of 'Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia'. Together they form a unique fingerprint.

Cite this